Placeholder Banner

Vical Licensee Completes Enrollment in Phase 3 Trial

September 28, 2009
Vical Incorporated (Nasdaq:VICL) licensee, sanofi-aventis, has completed enrollment in a 500-patient Phase 3 clinical trial of its angiogenesis therapy. The NV1FGF therapy contains DNA encoding Fibroblast Growth Factor 1 (FGF-1), a growth factor that stimulates the growth of blood vessels, and is intended to reduce the need for amputations in patients suffering from critical limb ischemia. The primary objective of the TAMARIS study is to demonstrate the superiority of NV1FGF treatment over placebo in the prevention of major amputation above the ankle of the treated leg or of death from any cause, whichever comes first, in critical limb ischemia patients with skin lesions. Sanofi-aventis expects to release final trial data in late 2010.

Read the release.